Chemotherapy with anti-HER2 is the standard treatment for HER2-positive breast cancer; however, a treatment strategy after treatment with trastuzumab deruxtecan (T-Dxd) and trastuzumab emtansine (T-DM1) has not been established. This evidence concerns the gene ERBB2 and breast cancer.